CLINICAL_TRIALS
trial_result
· 2024-10-26
Clinical Trial Update: Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
Summary
Pfizer reports completion of a special investigation evaluating tofacitinib (Xeljanz) for rheumatoid arthritis, with results posted on 2024-10-26.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Status: COMPLETED | Results posted: 2024-10-26